Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rec.2023.06.007 | DOI Listing |
Ann Thorac Surg Short Rep
December 2024
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio.
A 67-year-old man with aortic valve endocarditis presented with acute ST-segment elevation myocardial infarction and was found to have embolic vegetation occlusion of the left anterior descending coronary artery. This patient was successfully treated with early aortic valve replacement, extraction of a vegetation embolus, and coronary artery bypass grafting over the site of extraction.
View Article and Find Full Text PDFCardiovasc Diagn Ther
December 2024
Cardiology, Vascular Medicine & Pneumology, GRN Hospital Weinheim, Weinheim, Germany.
Cardiovasc Diagn Ther
December 2024
Department of Cardiovascular, University Hospital Basel, Basel, Switzerland.
Ann Thorac Surg Short Rep
June 2024
Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York.
We describe a rare but interesting complication of totally endoscopic robotic mitral valve repair in a patient with severe mitral regurgitation. The mitral valve was repaired robotically by standard techniques, and the intraoperative transesophageal echocardiogram demonstrated no residual mitral regurgitation. However, there was unexpected hypokinesia of the posterior and lateral walls of the left ventricle, with subsequent electrocardiography showing acute ST elevations of the lateral segment.
View Article and Find Full Text PDFAm J Cardiol
January 2025
Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Baim Institute for Clinical Research, Boston, MA, USA. Electronic address:
There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO). A previously-described blood biomarker panel to predict cardiovascular (CV) events was evaluated in patients with CTO. From 1251 patients in the CASABLANCA study, 241 participants with a CTO were followed for an average of 4 years for occurrence of major adverse CV events (MACE, CV death, non-fatal myocardial infarction or stroke) and CV death/heart failure (HF) hospitalization.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!